Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study

You Bin Lee; Bongsung Kim; Kyungdo Han; Jung A. Kim; Eun Roh; So Hyeon Hong; Kyung Mook Choi; Sei-Hyun Baik; Hye Jin Yoo

doi:10.12997/JLA.2021.10.3.303

Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study

You Bin Lee, Bongsung Kim, Kyungdo Han, Jung A. Kim, Eun Roh, So Hyeon Hong, Kyung Mook Choi, Sei-Hyun Baik, Hye Jin Yoo

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Objective: We investigated the effects of statin-ezetimibe combination therapy compared with statin-only treatment on the hazard of incident type 2 diabetes (T2D), myocardial infarction (MI), and stroke among adults with impaired fasting glucose (IFG) in a real-world setting. Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this propensity-matched nationwide cohort study. Among 56,633 IFG patients without baseline cardiovascular disease (CVD) and/or T2D who initiated statin therapy with or without ezetimibe, 1,155 with statin-ezetimibe combination therapy were matched based on a propensity score at a 1:5 ratio with 5,775 patients who received statin monotherapy. The hazards of T2D, MI, and stroke were compared between these treatment groups. Results: The incidence rate per 1,000 person-years was 19.62 (statin monotherapy group) and 21.02 (combined treatment group) for T2D, 1.53 (statin monotherapy group) and 1.70 (combined treatment group) for MI, and 1.99 (statin monotherapy group) and 2.06 (combined treatment group) for stroke. The hazards of T2D, MI, and stroke were not significantly different between the statin monotherapy group and the statin-ezetimibe combination therapy group. Conclusion: The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.

Original language	English
Pages (from-to)	303-312
Number of pages	10
Journal	Journal of Lipid and Atherosclerosis
Volume	10
Issue number	3
DOIs	https://doi.org/10.12997/JLA.2021.10.3.303
Publication status	Published - 2021 Sept

Bibliographical note

Funding Information:
This study was supported by the 2019 big data analysis grant from the Korean Society of Lipid and Atherosclerosis. The funding agency had no role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

Publisher Copyright:
© 2021 The Korean Society of Lipid and Atherosclerosis.

Keywords

Cardiovascular diseases
Ezetimibe
Prediabetic state
Statin
Type 2 diabetes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Endocrinology, Diabetes and Metabolism
Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.12997/JLA.2021.10.3.303

Fingerprint

Dive into the research topics of 'Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study'. Together they form a unique fingerprint.

Cite this

Lee, Y. B., Kim, B., Han, K., Kim, J. A., Roh, E., Hong, S. H., Choi, K. M., Baik, S.-H., & Yoo, H. J. (2021). Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study. Journal of Lipid and Atherosclerosis, 10(3), 303-312. https://doi.org/10.12997/JLA.2021.10.3.303

Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study. / Lee, You Bin; Kim, Bongsung; Han, Kyungdo et al.
In: Journal of Lipid and Atherosclerosis, Vol. 10, No. 3, 09.2021, p. 303-312.

Research output: Contribution to journal › Article › peer-review

Lee, YB, Kim, B, Han, K, Kim, JA, Roh, E, Hong, SH, Choi, KM, Baik, S-H & Yoo, HJ 2021, 'Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study', Journal of Lipid and Atherosclerosis, vol. 10, no. 3, pp. 303-312. https://doi.org/10.12997/JLA.2021.10.3.303

@article{3dfab75169284d5a8adbad076c8518b7,

title = "Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study",

abstract = "Objective: We investigated the effects of statin-ezetimibe combination therapy compared with statin-only treatment on the hazard of incident type 2 diabetes (T2D), myocardial infarction (MI), and stroke among adults with impaired fasting glucose (IFG) in a real-world setting. Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this propensity-matched nationwide cohort study. Among 56,633 IFG patients without baseline cardiovascular disease (CVD) and/or T2D who initiated statin therapy with or without ezetimibe, 1,155 with statin-ezetimibe combination therapy were matched based on a propensity score at a 1:5 ratio with 5,775 patients who received statin monotherapy. The hazards of T2D, MI, and stroke were compared between these treatment groups. Results: The incidence rate per 1,000 person-years was 19.62 (statin monotherapy group) and 21.02 (combined treatment group) for T2D, 1.53 (statin monotherapy group) and 1.70 (combined treatment group) for MI, and 1.99 (statin monotherapy group) and 2.06 (combined treatment group) for stroke. The hazards of T2D, MI, and stroke were not significantly different between the statin monotherapy group and the statin-ezetimibe combination therapy group. Conclusion: The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.",

keywords = "Cardiovascular diseases, Ezetimibe, Prediabetic state, Statin, Type 2 diabetes",

author = "Lee, {You Bin} and Bongsung Kim and Kyungdo Han and Kim, {Jung A.} and Eun Roh and Hong, {So Hyeon} and Choi, {Kyung Mook} and Sei-Hyun Baik and Yoo, {Hye Jin}",

note = "Funding Information: This study was supported by the 2019 big data analysis grant from the Korean Society of Lipid and Atherosclerosis. The funding agency had no role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2021 The Korean Society of Lipid and Atherosclerosis.",

year = "2021",

month = sep,

doi = "10.12997/JLA.2021.10.3.303",

language = "English",

volume = "10",

pages = "303--312",

journal = "Journal of Lipid and Atherosclerosis",

issn = "2287-2892",

publisher = "Korean Society of Lipid and Atherosclerosis",

number = "3",

}

TY - JOUR

T1 - Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose

T2 - A propensity-matched nationwide cohort study

AU - Lee, You Bin

AU - Kim, Bongsung

AU - Han, Kyungdo

AU - Kim, Jung A.

AU - Roh, Eun

AU - Hong, So Hyeon

AU - Choi, Kyung Mook

AU - Baik, Sei-Hyun

AU - Yoo, Hye Jin

N1 - Funding Information: This study was supported by the 2019 big data analysis grant from the Korean Society of Lipid and Atherosclerosis. The funding agency had no role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. Publisher Copyright: © 2021 The Korean Society of Lipid and Atherosclerosis.

PY - 2021/9

Y1 - 2021/9

N2 - Objective: We investigated the effects of statin-ezetimibe combination therapy compared with statin-only treatment on the hazard of incident type 2 diabetes (T2D), myocardial infarction (MI), and stroke among adults with impaired fasting glucose (IFG) in a real-world setting. Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this propensity-matched nationwide cohort study. Among 56,633 IFG patients without baseline cardiovascular disease (CVD) and/or T2D who initiated statin therapy with or without ezetimibe, 1,155 with statin-ezetimibe combination therapy were matched based on a propensity score at a 1:5 ratio with 5,775 patients who received statin monotherapy. The hazards of T2D, MI, and stroke were compared between these treatment groups. Results: The incidence rate per 1,000 person-years was 19.62 (statin monotherapy group) and 21.02 (combined treatment group) for T2D, 1.53 (statin monotherapy group) and 1.70 (combined treatment group) for MI, and 1.99 (statin monotherapy group) and 2.06 (combined treatment group) for stroke. The hazards of T2D, MI, and stroke were not significantly different between the statin monotherapy group and the statin-ezetimibe combination therapy group. Conclusion: The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.

AB - Objective: We investigated the effects of statin-ezetimibe combination therapy compared with statin-only treatment on the hazard of incident type 2 diabetes (T2D), myocardial infarction (MI), and stroke among adults with impaired fasting glucose (IFG) in a real-world setting. Methods: The Korean National Health Insurance Service datasets from 2002 to 2017 were used for this propensity-matched nationwide cohort study. Among 56,633 IFG patients without baseline cardiovascular disease (CVD) and/or T2D who initiated statin therapy with or without ezetimibe, 1,155 with statin-ezetimibe combination therapy were matched based on a propensity score at a 1:5 ratio with 5,775 patients who received statin monotherapy. The hazards of T2D, MI, and stroke were compared between these treatment groups. Results: The incidence rate per 1,000 person-years was 19.62 (statin monotherapy group) and 21.02 (combined treatment group) for T2D, 1.53 (statin monotherapy group) and 1.70 (combined treatment group) for MI, and 1.99 (statin monotherapy group) and 2.06 (combined treatment group) for stroke. The hazards of T2D, MI, and stroke were not significantly different between the statin monotherapy group and the statin-ezetimibe combination therapy group. Conclusion: The combination of ezetimibe in addition to statin treatment was not associated with a significantly different risk of T2D and CVDs compared with statin monotherapy in Korean adults with IFG.

KW - Cardiovascular diseases

KW - Ezetimibe

KW - Prediabetic state

KW - Statin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85118496636&partnerID=8YFLogxK

U2 - 10.12997/JLA.2021.10.3.303

DO - 10.12997/JLA.2021.10.3.303

M3 - Article

AN - SCOPUS:85118496636

SN - 2287-2892

VL - 10

SP - 303

EP - 312

JO - Journal of Lipid and Atherosclerosis

JF - Journal of Lipid and Atherosclerosis

IS - 3

ER -

Combination of statin and ezetimibe versus statin monotherapy on cardiovascular disease and type 2 diabetes incidence among adults with impaired fasting glucose: A propensity-matched nationwide cohort study

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this